Key Points
- CEO Martine Rothblatt sold 2,000 UTHR shares on Dec. 19 at an average price of $507.07 for $1,014,140, leaving her with 130 shares — a ~93.9% reduction in her reported position.
- The filings show Rothblatt sold a total of ~6,000 shares across Dec. 17–19 and other senior insiders also sold recently (CFO ~ $1.74M; COO ~ $11.17M), which may weigh on near‑term investor sentiment.
- United Therapeutics trades near a 12‑month high (~$517) with a market cap of $22.27B and a P/E of 19.6; analysts have an average rating of "Moderate Buy" and an average price target of $505.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Tommy Thompson sold 910 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $500.59, for a total value of $455,536.90. Following the sale, the director directly owned 8,480 shares in the company, valued at $4,245,003.20. This trade represents a 9.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
United Therapeutics Stock Performance
Shares of NASDAQ:UTHR opened at $517.13 on Friday. The business has a 50-day simple moving average of $463.63 and a two-hundred day simple moving average of $380.56. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $518.61. The firm has a market cap of $22.27 billion, a price-to-earnings ratio of 19.60, a price-to-earnings-growth ratio of 5.03 and a beta of 0.86.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts' consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm's revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.39 EPS. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AIA Group Ltd purchased a new position in shares of United Therapeutics in the third quarter worth $545,000. Allworth Financial LP increased its holdings in United Therapeutics by 26.1% in the 3rd quarter. Allworth Financial LP now owns 449 shares of the biotechnology company's stock valued at $188,000 after acquiring an additional 93 shares during the last quarter. Cambria Investment Management L.P. boosted its holdings in shares of United Therapeutics by 20.9% during the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company's stock valued at $1,114,000 after purchasing an additional 460 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of United Therapeutics by 66.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company's stock valued at $299,000 after purchasing an additional 284 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of United Therapeutics during the third quarter valued at about $644,000. 94.08% of the stock is currently owned by institutional investors.
United Therapeutics News Roundup
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
- Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
- Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
- Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. UBS Group boosted their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the company a "buy" rating in a research report on Thursday, November 6th. Royal Bank Of Canada lifted their target price on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. Bank of America upped their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a research note on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $505.00.
Get Our Latest Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
